Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.
Metrics to compare | ZURA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipZURAPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.8x | −4.0x | −0.6x | |
PEG Ratio | −0.03 | −0.21 | 0.00 | |
Price / Book | 0.8x | 4.1x | 2.6x | |
Price / LTM Sales | - | 13.4x | 3.1x | |
Upside (Analyst Target) | - | 290.2% | 51.5% | |
Fair Value Upside | Unlock | 22.4% | 8.4% | Unlock |